نتایج جستجو برای: telaprevir

تعداد نتایج: 686  

Journal: :The New England journal of medicine 2011
Ira M Jacobson John G McHutchison Geoffrey Dusheiko Adrian M Di Bisceglie K Rajender Reddy Natalie H Bzowej Patrick Marcellin Andrew J Muir Peter Ferenci Robert Flisiak Jacob George Mario Rizzetto Daniel Shouval Ricard Sola Ruben A Terg Eric M Yoshida Nathalie Adda Leif Bengtsson Abdul J Sankoh Tara L Kieffer Shelley George Robert S Kauffman Stefan Zeuzem

BACKGROUND In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has shown improved efficacy, with potential for shortening the duration of treatment in a majority of patients. METHODS In this international, phase 3, randomized, double-blind, placebo-controlled trial,...

Journal: :Roumanian archives of microbiology and immunology 2015
Sorin Dinu Petre-Iacob Calistru Emanoil Ceauşu Graţiela Târdeil Gabriela Oprişan

Although the European recommendations include the use of new antiviral drugs for the treatment of hepatitis C, in Romania the current treatment remains interferon plus ribavirin. First generation viral protease inhibitors (i.e. boceprevir, telaprevir), which have raised the chances of obtaining viral clearance in up to 70% of infection cases produced by genotype 1 isolates, have not been introd...

2012
Yuan Kong Xiaoping Wang Yushu Shang Paul M. Schroder Wenhua Liang Xiaoting Ling Zhiyong Guo Xiaoshun He

BACKGROUND Chronic hepatitis C virus (HCV) infection is one of the leading causes of hepatic cirrhosis and hepatocellular carcinoma, and HCV genotype 1 is the most prevalent genotype and is resistant to current standard therapy. We performed this meta-analysis to evaluate the efficacy and safety of telaprevir-based therapy for chronic HCV genotype 1 infection. METHODS We included randomized c...

2016
Tatsuo Kanda Shingo Nakamoto Reina Sasaki Masato Nakamura Shin Yasui Yuki Haga Sadahisa Ogasawara Akinobu Tawada Makoto Arai Shigeru Mikami Fumio Imazeki Osamu Yokosuka

BACKGROUND Direct-acting antiviral agents against HCV with or without peginterferon plus ribavirin result in higher eradication rates of HCV and shorter treatment duration. We examined which is better for predicting persistent virologic response, the assessment of serum HCV RNA at 12 or 24 weeks after the end of treatment for predicting sustained virologic response (SVR12 or SVR24, respectively...

Journal: :Hepatitis Monthly 2015

2012
Kristen M Marks Ira M Jacobson

Boceprevir and telaprevir are peptidomimetic serine protease inhibitors that have been recently approved for the treatment of HCV chronic infection. The addition of these drugs to the prior standard of care, pegylated interferon and ribavirin, improves sustained virological response rates for treatment-naive and treatment-experienced patients and shortens the duration of treatment for over half...

2013
Rolf van Heeswijk Peter Verboven Ann Vandevoorde Petra Vinck Griet Boogaerts Els De Paepe Rodica Van Solingen-Ristea Varun Garg

Journal: :Chemical communications 2010
Anass Znabet Marloes M Polak Elwin Janssen Frans J J de Kanter Nicholas J Turner Romano V A Orru Eelco Ruijter

A very short and efficient synthesis of the important drug candidate telaprevir, featuring a biocatalytic desymmetrization and two multicomponent reactions as the key steps, is presented. The classical issue of lack of stereoselectivity in Ugi- and Passerini-type reactions is circumvented. The atom economic and convergent nature of the synthetic strategy require only very limited use of protect...

Journal: :MMW - Fortschritte der Medizin 2012

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید